Serena Yun-Chen Tsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Serena Yun-Chen Tsai has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Kevin Sheng-Kai Ma
Department of Dermatology Massachusetts General Hospital Boston Massachusetts USA
8 shared publications Elena B. Hawryluk
Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Dermatology Section, Department of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
3 shared publicationsAshwin N. Ananthakrishnan
Division of Gastroenterology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publicationsBethany Brumbaugh
Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2 shared publications- Carlos Arturo Camargo
Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, United States
2 shared publications - Elena Balestreire Hawryluk
Department of Dermatology Massachusetts General Hospital Boston Massachusetts USA
2 shared publications
Latest Publications
- 24 June 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (3) , 396-397
Refining pediatric eczema severity assessment with Three-Item Severity score and Patient Oriented Eczema Measure
- 24 June 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (3) , 396-397
Refining pediatric eczema severity assessment with Three-Item Severity score and Patient Oriented Eczema Measure
- Open Access
- 18 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1698-1700
Effect of Diuretics on Cutaneous Squamous Cell Carcinoma: Clinical and Translational Evidence
- 18 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1698-1700
Open AccessEffect of Diuretics on Cutaneous Squamous Cell Carcinoma: Clinical and Translational Evidence
- 19 February 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (2) , 2502432
Reply: Addressing unmeasured confounding and detection bias in dupilumab–lymphoma association
- 19 February 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (2) , 2502432
Reply: Addressing unmeasured confounding and detection bias in dupilumab–lymphoma association
- Open Access
- 25 November 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (2) , 503-507
Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation
- 25 November 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (2) , 503-507
Open AccessComparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation
- Open Access
- 8 October 2025
- Published by Springer Nature in Pediatric Drugs
- Vol. 27 (6) , 761-770
Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study
Pediatric-onset inflammatory bowel diseases (IBD) are associated with an elevated risk of venous thromboembolism (VTE). However, data on the VTE risk in these patients treated with novel biologics, particularly vedolizumab, remain limited. To evaluate the association between vedolizumab and the risk of VTE compared with other biologics in patients with pediatric-onset Crohn's disease (CD) or ulcerative colitis (UC). We emulated a target trial using electronic health records from the TriNetX research network. The study included patients with CD or UC diagnosed before the age of 18 years who were treated with vedolizumab, ustekinumab, or anti-tumor necrosis factor (TNF) agents. Comparative groups were generated using 1:1 propensity-score matching based on relevant confounders. The primary outcome was the occurrence of any VTE within 12 months of follow-up. Cox proportional hazards models were used to compare the risk of VTE between vedolizumab-treated patients and those treated with anti-TNF agents and ustekinumab. A total of 1806 matched patient pairs were analyzed across four comparisons: patients treated with vedolizumab versus anti-TNF agents (CD = 407 pairs; UC = 443 pairs), and vedolizumab versus ustekinumab (CD = 563 pairs; UC = 393 pairs), respectively. Patients with CD receiving vedolizumab had a significantly higher risk of VTE compared with those receiving anti-TNF therapy (hazard ratio [HR] 8.63; 95% confidence interval [CI] 1.08-69.10; p = 0.014). A higher VTE risk was also observed in vedolizumab-treated patients with CD compared with those treated with ustekinumab (HR 4.64; 95% CI 1.35-15.97; p = 0.007). In contrast, no significant difference in VTE risk was found between vedolizumab and either comparator group in patients with UC. Treatment with vedolizumab was associated with a higher incidence of VTE than anti-TNF agents or ustekinumab among individuals with CD. Prospective cohort studies are warranted to validate the safety of biologic therapy for pediatric patients with CD.
- 8 October 2025
- Published by Springer Nature in Pediatric Drugs
- Vol. 27 (6) , 761-770
Open AccessVedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study
Pediatric-onset inflammatory bowel diseases (IBD) are associated with an elevated risk of venous thromboembolism (VTE). However, data on the VTE risk in these patients treated with novel biologics, particularly vedolizumab, remain limited. To evaluate the association between vedolizumab and the risk of VTE compared with other biologics in patients with pediatric-onset Crohn's disease (CD) or ulcerative colitis (UC). We emulated a target trial using electronic health records from the TriNetX research network. The study included patients with CD or UC diagnosed before the age of 18 years who were treated with vedolizumab, ustekinumab, or anti-tumor necrosis factor (TNF) agents. Comparative groups were generated using 1:1 propensity-score matching based on relevant confounders. The primary outcome was the occurrence of any VTE within 12 months of follow-up. Cox proportional hazards models were used to compare the risk of VTE between vedolizumab-treated patients and those treated with anti-TNF agents and ustekinumab. A total of 1806 matched patient pairs were analyzed across four comparisons: patients treated with vedolizumab versus anti-TNF agents (CD = 407 pairs; UC = 443 pairs), and vedolizumab versus ustekinumab (CD = 563 pairs; UC = 393 pairs), respectively. Patients with CD receiving vedolizumab had a significantly higher risk of VTE compared with those receiving anti-TNF therapy (hazard ratio [HR] 8.63; 95% confidence interval [CI] 1.08-69.10; p = 0.014). A higher VTE risk was also observed in vedolizumab-treated patients with CD compared with those treated with ustekinumab (HR 4.64; 95% CI 1.35-15.97; p = 0.007). In contrast, no significant difference in VTE risk was found between vedolizumab and either comparator group in patients with UC. Treatment with vedolizumab was associated with a higher incidence of VTE than anti-TNF agents or ustekinumab among individuals with CD. Prospective cohort studies are warranted to validate the safety of biologic therapy for pediatric patients with CD.
- Open Access
- 20 August 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (11) , 3143-3145.e1
Adjunctive therapy use following Janus kinase inhibitors versus dupilumab in atopic dermatitis
- 20 August 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (11) , 3143-3145.e1
Open AccessAdjunctive therapy use following Janus kinase inhibitors versus dupilumab in atopic dermatitis
- Top Cited Papers
- 19 June 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (3) , 2500139
Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study
Background: Dupilumab is approved for the treatment of atopic dermatitis, asthma, and other allergic diseases. Recent studies suggest that patients with atopic dermatitis receiving dupilumab are at a higher risk of developing cutaneous lymphoma. This study aimed to investigate the risk of lymphoma among patients with asthma receiving dupilumab. Methods: This population-based cohort study included patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. Propensity score matching was used to balance baseline characteristics between groups. The primary outcome was new-onset lymphoma, and secondary outcomes included other malignancies and all-cause mortality. Results: A total of 14 936 dupilumab-treated and 734 126 ICS/LABA-treated patients with asthma were included. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19–2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82–11.53). There was no significant difference in incidence of other malignant neoplasms. Dupilumab was also associated with significantly lower all-cause mortality (328 versus 793 deaths, HR 0.65, 95% CI 0.57–0.74). Conclusions: Dupilumab treatment was associated with lower all-cause mortality among patients with asthma, despite increased risk of lymphoma, particularly T-cell and NK-cell lymphomas. These findings highlight the need for long-term surveillance and further research into the immunological mechanisms underlying dupilumab-associated lymphoma in asthma.
- 19 June 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (3) , 2500139
Top Cited PapersDupilumab and lymphoma risk among patients with asthma: a population-based cohort study
Background: Dupilumab is approved for the treatment of atopic dermatitis, asthma, and other allergic diseases. Recent studies suggest that patients with atopic dermatitis receiving dupilumab are at a higher risk of developing cutaneous lymphoma. This study aimed to investigate the risk of lymphoma among patients with asthma receiving dupilumab. Methods: This population-based cohort study included patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. Propensity score matching was used to balance baseline characteristics between groups. The primary outcome was new-onset lymphoma, and secondary outcomes included other malignancies and all-cause mortality. Results: A total of 14 936 dupilumab-treated and 734 126 ICS/LABA-treated patients with asthma were included. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19–2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82–11.53). There was no significant difference in incidence of other malignant neoplasms. Dupilumab was also associated with significantly lower all-cause mortality (328 versus 793 deaths, HR 0.65, 95% CI 0.57–0.74). Conclusions: Dupilumab treatment was associated with lower all-cause mortality among patients with asthma, despite increased risk of lymphoma, particularly T-cell and NK-cell lymphomas. These findings highlight the need for long-term surveillance and further research into the immunological mechanisms underlying dupilumab-associated lymphoma in asthma.
- 3 April 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (4) , 306-311
Combination Laser Treatment in Procedural Management of Congenital Melanocytic Nevi
Background: Congenital melanocytic nevi (CMN) are benign melanocytic proliferations present at birth. Surgical excision has traditionally been the first‐line management for CMN removal; however, it may result in scars and potential disfigurement. Multiple clinical studies have demonstrated the effects of laser treatment for CMN, but data on fair‐skinned subjects remain limited.Objectives: To report the outcomes of combination laser therapy for CMN in pediatric patients.Methods: A retrospective review was conducted on the electronic medical records of patients under 18 years of age with CMN of any size who underwent an operating room procedure at Massachusetts General Hospital between January 1, 2010, and December 31, 2022. Laser types and settings were determined by the treating physician. The age, gender, race, Fitzpatrick skin type, size of nevus, treated area, number of treatments, interval between sessions, laser device, treatment response, complication, and follow‐up duration were collected.Results: Of 158 children with CMN, 13 were treated with laser therapy alone. Most patients had Fitzpatrick skin type I–III and large‐to‐giant CMN with facial involvement. They were typically treated with a combination of a long‐pulsed laser and a Q‐switched laser, followed by a resurfacing laser. The median number of total treatments was 7. The laser treatment achieved pigment reduction in all patients as expected, with no disfiguring scarring, unsatisfactory dyspigmentation, or adverse events observed during follow‐up visits.Conclusions: We conclude that CMN in children with lighter skin types can be effectively treated using a strategic combination of different laser devices over multiple sessions for cosmetic purposes.
- 3 April 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (4) , 306-311
Combination Laser Treatment in Procedural Management of Congenital Melanocytic Nevi
Background: Congenital melanocytic nevi (CMN) are benign melanocytic proliferations present at birth. Surgical excision has traditionally been the first‐line management for CMN removal; however, it may result in scars and potential disfigurement. Multiple clinical studies have demonstrated the effects of laser treatment for CMN, but data on fair‐skinned subjects remain limited.Objectives: To report the outcomes of combination laser therapy for CMN in pediatric patients.Methods: A retrospective review was conducted on the electronic medical records of patients under 18 years of age with CMN of any size who underwent an operating room procedure at Massachusetts General Hospital between January 1, 2010, and December 31, 2022. Laser types and settings were determined by the treating physician. The age, gender, race, Fitzpatrick skin type, size of nevus, treated area, number of treatments, interval between sessions, laser device, treatment response, complication, and follow‐up duration were collected.Results: Of 158 children with CMN, 13 were treated with laser therapy alone. Most patients had Fitzpatrick skin type I–III and large‐to‐giant CMN with facial involvement. They were typically treated with a combination of a long‐pulsed laser and a Q‐switched laser, followed by a resurfacing laser. The median number of total treatments was 7. The laser treatment achieved pigment reduction in all patients as expected, with no disfiguring scarring, unsatisfactory dyspigmentation, or adverse events observed during follow‐up visits.Conclusions: We conclude that CMN in children with lighter skin types can be effectively treated using a strategic combination of different laser devices over multiple sessions for cosmetic purposes.
- 28 December 2024
- Published by Elsevier in The Journal of Pediatrics
- Vol. 279, 114458
Increasing Incidence of Serious Head and Neck Infections among Children in the United States, 2018-2023
- 28 December 2024
- Published by Elsevier in The Journal of Pediatrics
- Vol. 279, 114458
Increasing Incidence of Serious Head and Neck Infections among Children in the United States, 2018-2023
- Open Access
Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study
Background: Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD. Methods: In this population‐based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (<18 years of age) with a diagnosis of AD initiating dupilumab were propensity‐score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new‐onset comorbidities emerging during the study period measured by the risk ratio (RR) and its confidence interval (CI). Subgroup analyses were stratified by age (0–5 years, 6–11 years, and 12–17 years), sex, and race. Results: A total of 3575 pediatric patients with AD treated with dupilumab were matched to 3575 patients treated with other systemic agents. The dupilumab cohort was associated with a lowered risk of new‐onset atopic comorbidities (including asthma [RR, 0.72; 95% CI, 0.59–0.89] and allergic rhinitis [RR, 0.62; 95% CI, 0.52–0.74]), infections (e.g., skin and soft tissue infection [RR, 0.70; 95% CI, 0.63–0.76] and respiratory tract infection [RR = 0.56; 95% CI, 0.51–0.61]), psychiatric disorders (e.g., mood disorder [RR, 0.52; 95% CI, 0.39–0.70] and anxiety [RR, 0.57; 95% CI, 0.46–0.70], sleep disturbance [RR, 0.60; 95% CI, 0.47–0.77]), neurologic and developmental disorders (e.g., attention deficit hyperactivity disorder [RR, 0.54; 95% CI, 0.38–0.75]). Furthermore, the positive effects are found to be more pronounced in younger children (aged 0–5 years) with AD. Conclusions: Treatment with dupilumab compared to systemic agents resulted in reductions in AD‐related comorbidities in pediatric patients.
Open AccessEvaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study
Background: Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD. Methods: In this population‐based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (<18 years of age) with a diagnosis of AD initiating dupilumab were propensity‐score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new‐onset comorbidities emerging during the study period measured by the risk ratio (RR) and its confidence interval (CI). Subgroup analyses were stratified by age (0–5 years, 6–11 years, and 12–17 years), sex, and race. Results: A total of 3575 pediatric patients with AD treated with dupilumab were matched to 3575 patients treated with other systemic agents. The dupilumab cohort was associated with a lowered risk of new‐onset atopic comorbidities (including asthma [RR, 0.72; 95% CI, 0.59–0.89] and allergic rhinitis [RR, 0.62; 95% CI, 0.52–0.74]), infections (e.g., skin and soft tissue infection [RR, 0.70; 95% CI, 0.63–0.76] and respiratory tract infection [RR = 0.56; 95% CI, 0.51–0.61]), psychiatric disorders (e.g., mood disorder [RR, 0.52; 95% CI, 0.39–0.70] and anxiety [RR, 0.57; 95% CI, 0.46–0.70], sleep disturbance [RR, 0.60; 95% CI, 0.47–0.77]), neurologic and developmental disorders (e.g., attention deficit hyperactivity disorder [RR, 0.54; 95% CI, 0.38–0.75]). Furthermore, the positive effects are found to be more pronounced in younger children (aged 0–5 years) with AD. Conclusions: Treatment with dupilumab compared to systemic agents resulted in reductions in AD‐related comorbidities in pediatric patients.